# Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults

> **NCT03408899** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 13 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** PC-1005 gel

## Key facts

- **NCT ID:** NCT03408899
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-19
- **Primary completion:** 2019-04-19
- **Final completion:** 2019-04-19
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2023-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03408899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03408899, "Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03408899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*